KalVista Highlights Sebetralstat’s Potential at Medical Congress
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new setralstat findings related to time to end of progression of hereditary angioedema (HAE) attacks, and the effectiveness...